<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400021</url>
  </required_header>
  <id_info>
    <org_study_id>CTNPT025</org_study_id>
    <nct_id>NCT02400021</nct_id>
  </id_info>
  <brief_title>Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals</brief_title>
  <acronym>ProSPAR</acronym>
  <official_title>Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CIHR Canadian HIV Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In pregnancy, cART is considered optimal for maternal health and for preventing the emergence
      of resistance that could compromise further care. In Canada, the majority of HIV-positive
      pregnant women receive a PI-based cART regimen. In the past, therapy was generally deferred
      until after the first trimester (if not required for maternal health) to minimize any unknown
      risk of teratogenicity. However, as treatment is now started earlier in HIV infection and as
      perinatal transmission rates are lowest in those with prolonged suppression of viral load
      during pregnancy, women are increasingly commencing cART either before conception or earlier
      in pregnancy.

      Multiple reports and cohort studies provided data suggesting an association between PI-based
      cART use and preterm birth, low birth weight, and small for gestational age (SGA) babies,
      although conflicting data exist.

      In the general population progesterone supplementation is widely used, is well tolerated, is
      considered safe, and is beneficial to prevent recurrent pre-term birth and increase birth
      weight. The investigators experimental findings suggest that PI use during pregnancy is
      associated with declines in progesterone levels that correlate with fetal growth, and that
      progesterone supplementation can improve PI-induced fetal growth restriction. The
      investigators preliminary findings in HIV+ pregnant women suggest that PI-use is associated
      with declines in progesterone levels, which correlate with birth weight percentile. Since
      HIV-positive women have higher rates of pre-term delivery and low birth weight that may be
      magnified by the use of PIs, then progesterone supplementation could be of benefit to
      neonatal health in the context of HIV-positive pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total enrollment / eligible population per year</measure>
    <time_frame>12 months</time_frame>
    <description>Qualitative information on the reasons to decline participation will be collected and summarized. Reasons for non-enrolling questionnaire will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of progesterone supplementation during pregnancy for HIV-positive women.</measure>
    <time_frame>40 weeks</time_frame>
    <description>The number of Grade 3 or 4 AE in the ITT vs. comparator group. The number of Grade 1 or 2 AE in the ITT vs. comparator group. AE questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of progesterone supplementation during pregnancy for HIV+ women.</measure>
    <time_frame>40 weeks</time_frame>
    <description>Assessed in the ITT group. Acceptability based on experience with medication questionnaire. Screening questionnaire (acceptability of being recruited to no treatment arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance of progesterone supplementation. Assessed in the ITT group.</measure>
    <time_frame>40 weeks</time_frame>
    <description>Number of missed doses / total prescribed doses per patient. Compliance questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barriers to adherence to progesterone supplementation. Assessed in the ITT group</measure>
    <time_frame>40 weeks</time_frame>
    <description>Reasons for missed dose questionnaire. Reasons for missed appointment questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum progesterone levels at GW25-28 and GW33-36, described by treatment group.</measure>
    <time_frame>28 weeks, 36 weeks</time_frame>
    <description>SD and intra-patient correlation coefficient of trough serum progesterone levels will be calculated</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine progesterone levels at GW25-28 and GW33-36, described by treatment group</measure>
    <time_frame>28 weeks, 36 weeks</time_frame>
    <description>SD and intra-patient correlation coefficient will be calculated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Distribution of birth weight, birth weight percentile, and gestational age at birth, compared by treatment group.</measure>
    <time_frame>40 weeks</time_frame>
    <description>ITT and on-treatment analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between progesterone levels (serum or urine) at GW25-28 or GW33-36 and birth weight, birth weight percentile, and gestation age at birth.</measure>
    <time_frame>28 weeks, 36 weeks</time_frame>
    <description>assessed with spearman's rank correlation</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum/urine progesterone levels compared between women with and without an AE/SAE.</measure>
    <time_frame>40 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>40 weeks</time_frame>
    <description>levels of sex steroids, angiogenic, vasoactive, and inflammatory factors, factors associated with placentation, placenta dysfunction, pre-term delivery and fetal growth restriction between treatment groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Placenta morphology between treatment groups</measure>
    <time_frame>40 weeks</time_frame>
    <description>Qualitative assessment performed blinded to the arm allocation and birth outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Progesterone supplementation effect on PI drug levels</measure>
    <time_frame>40 weeks</time_frame>
    <description>trough PI drug levels in plasma collected from women in both tx groups at baseline and each study visit. changes in drug levels over time will be evaluated.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Prometrium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prometrium (progesterone capsules) intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prometrium</intervention_name>
    <arm_group_label>Prometrium</arm_group_label>
    <other_name>progesterone capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection

          -  On (stable) or initiating a cART regimen containing either ritonavir-boosted lopinavir
             (LPV/r), atazanavir (ATZ/r) or darunavir (DRV/r)

          -  Pregnant up to 24 weeks gestational age

          -  Singleton pregnancy

          -  18 years or older

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Hypersensitivity or allergy to soya or peanut (non-active ingredient supplement in
             Prometrium)

          -  Contraindications to intravaginal progesterone use including:

               -  documented hypersensitivity to Prometrium

               -  active or history of breast cancer,

               -  active or history of arterial thromboembolitic disease (e.g. stroke, myocardial
                  infarction, coronary heart disease)

               -  active or history of venous thromboembolism (e.g. deep venous thrombosis or
                  pulmonary embolism) or active thrombophlebitis

               -  any prior neoplasia, except for skin

               -  abnormal vaginal bleeding

          -  Known lethal fetal anomaly

          -  Any contraindication to continuation of pregnancy

          -  Inability to communicate in English

          -  Prior participation in this trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Walmsley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Research Institute, UHN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kellie Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital (Toronto, Ontario)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lena Serghides, PhD</last_name>
    <phone>647-230-7450</phone>
    <email>lena.serghides@utoronto.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lena Serghides</last_name>
      <phone>647-230-7450</phone>
      <email>lena.serghides@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Silverman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lena Serghides</last_name>
      <phone>647-230-7450</phone>
      <email>lena.serghides@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Mark Yudin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maple Leaf Medical Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1K2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lena Serghides</last_name>
      <phone>647-230-7450</phone>
      <email>lena.serghides@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Mona Loutfy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lena Serghides</last_name>
      <phone>647-230-7450</phone>
      <email>lena.serghides@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Kellie Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lena Serghides</last_name>
      <phone>647-230-7450</phone>
      <email>lena.serghides@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Sharon Walmsley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

